WMSA
CLDX icon

Weiss Multi-Strategy Advisers’s Celldex Therapeutics CLDX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,333
Closed -$312K – 917
2013
Q2 		$312K Buy
+1,333
New +$262K 0.01% 572

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Weiss Multi-Strategy Advisers's CLDX Position: Q3 2013 in Review

Weiss Multi-Strategy Advisers sold out of Celldex Therapeutics (CLDX) in Q3 2013, closing a stake of 1,333 shares — an estimated $312K sold.

Weiss Multi-Strategy Advisers first reported a position in CLDX in Q2 2013 and held it in 1 quarter. The position peaked at $312K in Q2 2013. 150 funds tracked by Wall St. Rank hold CLDX as of Q3 2013.

  • Weiss Multi-Strategy Advisers reported no remaining Celldex Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 1,333 Celldex Therapeutics shares in Q3 2013, an estimated $312K.
  • Weiss Multi-Strategy Advisers first reported a position in Celldex Therapeutics in Q2 2013 and held it in 1 quarter.
  • Weiss Multi-Strategy Advisers's Celldex Therapeutics position peaked at $312K in Q2 2013.
  • 150 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2013.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2013, filed 14 Nov 2013.